🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

97+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 97 recruiting trials for “acute-myeloid-leukemia

Phase 2RecruitingNCT05925504

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT05902416

Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome

🏥 Peking University People's Hospital📍 1 site📅 Started Jun 2023View details ↗
Phase 2RecruitingNCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

👨‍⚕️ Mark Juckett, University of Minnesota Masonic Cancer Center📍 1 site📅 Started May 2023View details ↗
Phase 1, PHASE2RecruitingNCT05732103

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

👨‍⚕️ Guillermo Garcia-Manero, MD, M.D. Anderson Cancer Center📍 7 sites📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05796570

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

👨‍⚕️ Franziska Wachter, MD, Dana-Farber Cancer Institute📍 2 sites📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05736965

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

🏥 Shanghai Tong Ren Hospital📍 19 sites📅 Started Feb 2023View details ↗
Phase 1RecruitingNCT05558124

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

👨‍⚕️ Onyee Chan, MD, Moffitt Cancer Center📍 1 site📅 Started Feb 2023View details ↗
Phase 3Enrolling by InvitationNCT05674539

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

👨‍⚕️ Linghui Xia, Professor, Department of Hematology, Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2023View details ↗
Phase 1RecruitingNCT05703542

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

👨‍⚕️ Eric S Winter, MD, Dana-Farber Cancer Institute📍 1 site📅 Started Feb 2023View details ↗
Phase 1RecruitingNCT04953910

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

🏥 Taiho Oncology, Inc.📍 22 sites📅 Started Dec 2022View details ↗
Phase 1, PHASE2RecruitingNCT05360160

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

👨‍⚕️ Ghayas Issa, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Oct 2022View details ↗
Phase 2RecruitingNCT05657639

CAV Regimen for R/R AML

🏥 The First Affiliated Hospital of Soochow University📍 1 site📅 Started Oct 2022View details ↗
Phase 2RecruitingNCT05365035

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

👨‍⚕️ Guillermo Bravo, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Sep 2022View details ↗
Phase 1RecruitingNCT05607199

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

👨‍⚕️ Akhil Kumar, MD, Head Clinical Development📍 5 sites📅 Started Sep 2022View details ↗
Phase 3RecruitingNCT04628026

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

👨‍⚕️ Hartmut Doehner, MD, University of Ulm📍 91 sites📅 Started Sep 2022View details ↗
RecruitingNCT05290662

Registry of Patients Having Received oNKord®

🏥 Glycostem Therapeutics BV📍 2 sites📅 Started Jun 2022View details ↗
Phase 1RecruitingNCT05342584

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

👨‍⚕️ Ioannis Mantzaris, MD, Montefiore Medical Center📍 1 site📅 Started May 2022View details ↗
NARecruitingNCT06328179

Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

🏥 Huai'an First People's Hospital📍 1 site📅 Started May 2022View details ↗
RecruitingNCT05326919

The Patient Cohort of the National Center for Precision Medicine in Leukemia

🏥 Assistance Publique - Hôpitaux de Paris📍 3 sites📅 Started Mar 2022View details ↗
Phase 2RecruitingNCT05184842

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

👨‍⚕️ Mendel Goldfinger, MD, Montefiore Medical Center📍 3 sites📅 Started Mar 2022View details ↗
← PreviousPage 4 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →